heart related News
-
VUNO Med-DeepECG Designated as Breakthrough Device
South Korean artificial intelligence (AI) developer, VUNO inc. announced that the Korean Ministry of Food and Drug Safety (KFDA) has designated the company’s artificial intelligence-based electrocardiogram (ECG) analysis software VUNO Med®-DeepECG™ as the ministry’s 16th Breakthrough Device. Using deep learning, the software analyzes ECG data to zero in on heart failure, ...
By Vuno Inc.
-
HSC Partners with CardiacSense for medical-grade wearables
CardiacSense is a leading manufacturer of a range of wearable devices for the continuous monitoring of heart arrhythmias and blood pressure HSC signs exclusive Distribution Agreement for Australia & New Zealand for watches & wristbands HomeStay to integrate CardiacSense solutions in HSC’s IoT Platform for assistive technology HomeStay Care Limited (ASX: HSC) ...
By CardiacSense
-
Endotronix Hires Industry Veteran Jim Yearick as Senior Vice President of Sales and Marketing
Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure, today announced that industry veteran Jim Yearick has joined the executive leadership team as Senior Vice President of Sales and Marketing. Mr. Yearick will oversee Endotronix’s worldwide sales and marketing efforts for the Cordella™ Heart Failure System (Cordella ...
-
Miracor Medical starts PiCSO-AMI-I randomized study in EU
Miracor Medical SA (Miracor Medical) today announced the initiation and first patient enrollment in the PICSO-AMI-I study to evaluate the benefits of PiCSO® therapy compared with conventional PCI for the treatment of anterior STEMI patients. The first patient enrolled into this study was treated at Oxford Heart Center, Oxford, UK by Professor Adrian Banning, the principal investigator of the ...
-
Sequana Medical completes enrollment in Phase 2a SAHARA I DSR study, reports disease-modifying profile for Short Term DSR and provides business update
DSR (Direct Sodium Removal) heart failure drug development: Completed enrollment in SAHARA I[i] with first-generation DSR product (“DSR 1.0”) – extending study with second-generation DSR product (“DSR 2.0”) to support US IND[ii] filing by year end Proof-of-concept delivered in diuretic-resistant heart failure patients with dramatic and durable improvements in ...
-
Endotronix Closes Expanded Series D Financing Round of $70 Million for Heart Failure Solution
Endotronix, Inc., a digital health, medtech company dedicated to advancing the treatment of heart failure (HF), today announced the expansion of its Series D financing round, bringing the total for the round to $70 million. The expansion syndicate for the LSP-led round includes new investment from an additional unnamed medical device strategic investor as well as participation from existing ...
-
Miracor Medical starts 2nd randomized study, targeting expanded indications
Miracor Medical SA (Miracor Medical) today announced the first patient enrolled in the PICSO-AMI-V study to evaluate the benefits of PiCSO® (Pressure-controlled intermittent Coronary Sinus Occlusion) therapy as an adjunct to conventional primary percutaneous coronary intervention (PCI) for patients presenting with inferior ST-Elevation Myocardial Infarction (STEMI). The first patient ...
-
BioVentrix Announces Jerry Estep, MD, as Co-Principal Investigator for ALIVE Pivotal Trial Studying a Transcatheter Device for Heart Failure
BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter Ventricular Restoration (TCVR), today announced that heart failure specialist Jerry Estep, MD, of the Cleveland Clinic has been appointed co-principal investigator of the pivotal ALIVE Trial studying LIVE Therapy using the Revivent TC TransCatheter Ventricular ...
-
Cardiac Dimensions Included in the New 2021 ESC Guidelines for Heart Failure Management
Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced the mention of their Carillon Mitral Contour System in the 2021 European Society of Cardiology (ESC) Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. In addition, the Carillon Mitral ...
-
Endotronix Appoints Industry Veteran Dan Dearen to Board of Directors
Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced the appointment of seasoned medical device industry executive Dan Dearen to its Board of Directors. Mr. Dearen currently serves as the President and Chief Financial Officer of Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology ...
-
Cardiac Dimensions Announces $17.5 Million Series C Financing to Accelerate Sales Expansion of the Carillon Mitral Contour System
Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, today announced the company has closed a $17.5 million Series C financing. All existing shareholders participated in the round including Aperture Venture Partners, Arboretum Ventures, Hostplus, Life Sciences Partners, Lumira ...
-
Creative Proteomics Lipidomics Upgrades Its Medium-Chain and Long-Chain Fatty Acids Analysis Service
Lipidomics, a platform developed by Creative Proteomics, is dedicated to providing cutting-edge mass spectrometry (MS)-based lipidomic research services for biomedical institutions as well as biotechnological and pharmaceutical companies. The company has recently upgraded its medium-chain and long-chain fatty acid analysis service. This service can provide reflections on lipid metabolism, glucose ...
-
The economic impact of noise pollution on human health
A recent report has assessed the latest research on the adverse affects of noise on health, focusing on approaches to estimating the economic cost of noise. This information could help policy makers tasked with designing cost-effective noise reduction and management policies. Increased traffic noise and the wider spread of a 24 hour society have contributed to rising complaints about ...
-
Cardiac Dimensions Welcomes Robert White to its Board of Directors
Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, today announced the election of Robert White as an independent director to its Board of Directors. Mr. White is a veteran medical technology executive, innovator and strategist with nearly 30 years of experience leading early-stage ...
-
Think Porthole: Challenges to imaging the heart with ultrasound
There is no doubt that 2-dimensional (2D) ultrasound imaging can be a challenging task to learn. Performing ultrasound requires some imagination. A simple turn of the transducer can change the orientation of anatomy. Therefore, learning anatomy in this way is not always straightforward as with 3-dimensional fixed images. To further complicate matters, the human body presents obstacles at nearly ...
-
Cardiac Dimensions Reaches 1,000 Implants of Carillon System, a Minimally Invasive Treatment for Functional Mitral Regurgitation
Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, today announced the Carillon Mitral Contour System® has been implanted in 1,000 patients in the United States, Europe, Australia, Turkey and the Middle East. The Carillon System is a right-heart transcatheter mitral valve ...
-
New Data Shows The Carillon Mitral Contour System Is Associated With Improvement In Regurgitant Volume In Patients With Increased Mitral Valve Tenting
Cardiac Dimensions, a leader in the development of minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, presented data at the TVT2019 Structural Heart Summit showing increased mitral valve tenting is associated with an improvement in regurgitant volume with the Carillon Mitral Contour System®. The Carillon System is a right-heart ...
-
Cardiac Dimensions Announces Launch of Its Optimized U.S. Pivotal Trial - The EMPOWER Trial
Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced the launch of the U.S. pivotal study The EMPOWER Trial. The EMPOWER Trial is evaluating the Carillon Mitral Contour System® for the treatment of heart failure patients with early-stage functional mitral ...
-
Cardiac Dimensions Announces Two New Meta-Analysis Publications Showing Statistically Significant and Clinically Meaningful Benefits to Heart Failure Patients Suffering from Functional Mitral Regurgitation
Cardiac Dimensions announced a published second individual patient data meta-analysis demonstrating clinically significant outcomes for the Carillon Mitral Contour System®. This publication, in addition to the several others recently published on the Carillon device, continues the series of excellent results for this transcatheter-based indirect annuloplasty device. Both of the published ...
-
Cardiac Dimensions Announces Australian Therapeutic Goods Administration’s Approval of the Carillon System for the Treatment of Functional Mitral Regurgitation
Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, today announced the Therapeutic Goods Administration (TGA) has approved its Carillon Mitral Contour System®. The Carillon System is a right heart transcatheter mitral valve repair (TMVr) device designed to treat the ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you